Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  García Arriaza, Juan ^a   Arnáez, Pilar ^a   Gómez, Carmen E ^a   Sorzano, Carlos Óscar S ^a   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERFERON; INTERFERON REGULATORY FACTOR 3; MODIFIED VACCINIA VIRUS ANKARA B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; RECOMBINANT VACCINE; VIRAL PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C6L GENE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG DESIGN; EFFECTOR CELL; FEMALE; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IFN ALPHA GENE; IFN BETA GENE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; INTRACELLULAR SIGNALING; K7R GENE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; TNF ALPHA GENE; VACCINATION; VACCINIA VIRUS; VIRUS GENE; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHICK EMBRYO; DENDRITIC CELL; GENE VECTOR; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INNATE IMMUNITY; MACROPHAGE; METABOLISM; POXVIRIDAE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; POXVIRIDAE; VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

ADAPTIVE IMMUNITY; AIDS VACCINES; ANIMALS; CELL LINE; CHICK EMBRYO; DENDRITIC CELLS; FEMALE; GENETIC VECTORS; HIV ANTIBODIES; HIV ANTIGENS; HIV-1; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; INTERFERONS; MACROPHAGES; MICE, INBRED BALB C; POXVIRIDAE; SEQUENCE DELETION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 84879530209     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066894     Document Type: Article

References (69)

1. Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M, (2012) Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother 8: 1192-1207.
2. Pantaleo G, Esteban M, Jacobs B, Tartaglia J, (2010) Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS 5: 391-396.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
4. Esteban M, (2009) Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccin 5: 867-871.
5. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, et al. (2006) Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24: 417-425.
6. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, et al. (2010) Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 5: e13983.
7. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, et al. (2011) Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 203: 610-619.
8. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, et al. (2006) Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 80: 4717-4728.
9. Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, et al. (2011) A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 29: 1948-1958.
10. Kutscher S, Allgayer S, Dembek CJ, Bogner JR, Protzer U, et al. (2010) MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays. Gene Ther 17: 1372-1383.
11. Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, et al. (2009) A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses 25: 1107-1116.
12. Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, et al. (2008) Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 198: 1482-1490.
13. Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, et al. (2010) Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One 5: e8816.
14. Garcia-Arriaza J, Najera JL, Gomez CE, Sorzano CO, Esteban M, (2010) Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One 5: e12395.
15. Garcia-Arriaza J, Najera JL, Gomez CE, Tewabe N, Sorzano CO, et al. (2011) A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One 6: e24244.
16. Gomez CE, Najera JL, Jimenez EP, Jimenez V, Wagner R, et al. (2007) Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine. 25: 2863-2885.
17. Gomez CE, Najera JL, Sanchez R, Jimenez V, Esteban M, (2009) Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine 27: 3165-3174.
18. Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, Beenhakker N, van Haaften P, et al. (2008) Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol 82: 2975-2988.
19. Garcia F, Bernaldo de Quiros JC, Gomez CE, Perdiguero B, Najera JL, et al. (2011) Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 29: 8309-8316.
20. Gomez CE, Najera JL, Perdiguero B, Garcia-Arriaza J, Sorzano CO, et al. (2011) The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol 85: 11468-11478.
21. Perdiguero B, Esteban M, (2009) The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 29: 581-598.
22. Gomez CE, Perdiguero B, Najera JL, Sorzano CO, Jimenez V, et al. (2012) Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 86: 5026-5038.
23. Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, et al. (2011) Improved NYVAC-based vaccine vectors. PLoS One 6: e25674.
24. Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, et al. (2011) Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One 6: e16819.
25. Antoine G, Scheiflinger F, Dorner F, Falkner FG, (1998) The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396.
26. Blanchard TJ, Alcami A, Andrea P, Smith GL, (1998) Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79 (Pt 5): 1159-1167.
27. Unterholzner L, Sumner RP, Baran M, Ren H, Mansur DS, et al. (2011) Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog 7: e1002247.
28. Gonzalez JM, Esteban M, (2010) A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol J 7: 59.
29. Sumner RP, Ren H, Smith GL (2013) Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J Gen Virol.
30. Oda S, Schroder M, Khan AR, (2009) Structural basis for targeting of human RNA helicase DDX3 by poxvirus protein K7. Structure 17: 1528-1537.
31. Kalverda AP, Thompson GS, Vogel A, Schroder M, Bowie AG, et al. (2009) Poxvirus K7 protein adopts a Bcl-2 fold: biochemical mapping of its interactions with human DEAD box RNA helicase DDX3. J Mol Biol 385: 843-853.
32. Schroder M, Baran M, Bowie AG, (2008) Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J 27: 2147-2157.
33. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M, (2011) MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 11: 189-217.
34. Climent N, Guerra S, Garcia F, Rovira C, Miralles L, et al. (2011) Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PLoS One 6: e19644.
35. Guerra S, Gonzalez JM, Climent N, Reyburn H, Lopez-Fernandez LA, et al. (2010) Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J Virol 84: 8141-8152.
36. Alcami A, (2003) Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 3: 36-50.
37. Alcami A, Smith GL, (2002) The vaccinia virus soluble interferon-gamma receptor is a homodimer. J Gen Virol 83: 545-549.
38. Alcami A, Symons JA, Smith GL, (2000) The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 74: 11230-11239.
39. Perdiguero B, Gomez CE, Najera JL, Sorzano CO, Delaloye J, et al. (2012) Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One 7: e48524.
40. Garber DA, O'Mara LA, Gangadhara S, McQuoid M, Zhang X, et al. (2012) Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol 86: 12605-12615.
41. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, et al. (2001) Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410: 106-111.
42. Sallusto F, Geginat J, Lanzavecchia A, (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22: 745-763.
43. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A, (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
44. Seder RA, Darrah PA, Roederer M, (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
45. Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, et al. (2007) Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS One 2: e321.
46. Hess C, Altfeld M, Thomas SY, Addo MM, Rosenberg ES, et al. (2004) HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet 363: 863-866.
47. Northfield JW, Loo CP, Barbour JD, Spotts G, Hecht FM, et al. (2007) Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point. J Virol 81: 5759-5765.
48. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
49. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, et al. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15: 293-299.
50. Freel SA, Saunders KO, Tomaras GD, (2011) CD8(+)T-cell-mediated control of HIV-1 and SIV infection. Immunol Res 49: 135-146.
51. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286.
52. Agy MB, Acker RL, Sherbert CH, Katze MG, (1995) Interferon treatment inhibits virus replication in HIV-1- and SIV-infected CD4+ T-cell lines by distinct mechanisms: evidence for decreased stability and aberrant processing of HIV-1 proteins. Virology 214: 379-386.
53. Baca-Regen L, Heinzinger N, Stevenson M, Gendelman HE, (1994) Alpha interferon-induced antiretroviral activities: restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes. J Virol 68: 7559-7565.
54. Barr SD, Smiley JR, Bushman FD, (2008) The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog 4: e1000007.
55. Coccia EM, Krust B, Hovanessian AG, (1994) Specific inhibition of viral protein synthesis in HIV-infected cells in response to interferon treatment. J Biol Chem 269: 23087-23094.
56. Fernie BF, Poli G, Fauci AS, (1991) Alpha interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphocytic cells. J Virol 65: 3968-3971.
57. Hansen MB, Svenson M, Bendtzen K, (1992) Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-alpha in normal human sera. Clin Exp Immunol 88: 559-562.
58. Shirazi Y, Pitha PM, (1992) Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. J Virol 66: 1321-1328.
59. Hughes R, Towers G, Noursadeghi M, (2012) Innate immune interferon responses to human immunodeficiency virus-1 infection. Rev Med Virol 22: 257-266.
60. Le Bon A, Tough DF, (2002) Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 14: 432-436.
61. Sato Y, Takatsu Y, Yamada T, Kataoka K, Taniguchi R, et al. (2000) Interferon treatment for dilated cardiomyopathy and striated myopathy associated with hepatitis C virus infection based on serial measurements of serum concentrations of cardiac troponin T. Jpn Circ J. 64: 321-324.
62. Wang F, Gao X, Barrett JW, Shao Q, Bartee E, et al. (2008) RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog 4: e1000099.
63. Falivene J, Del Medico Zajac MP, Pascutti MF, Rodriguez AM, Maeto C, et al. (2012) Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One 7: e32220.
64. Cottingham MG, Andersen RF, Spencer AJ, Saurya S, Furze J, et al. (2008) Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One 3: e1638.
65. Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, et al. (2009) Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One 4: e5445.
66. Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, et al. (2009) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5: e1000480.
67. Ramirez JC, Gherardi MM, Esteban M, (2000) Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74: 923-933.
68. Najera JL, Gomez CE, Garcia-Arriaza J, Sorzano CO, Esteban M, (2010) Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One 5: e11406.
69. Najera JL, Gomez CE, Domingo-Gil E, Gherardi MM, Esteban M, (2006) Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol 80: 6033-6047.